The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review
Irritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal tract. Its pathogenesis involves multiple factors, including visceral hypersensitivity and immune activation. NLRP3 inflammasome is part of the nucleotide-binding oligomerization domain-like receptor (NLR) family, a crucial...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/13/1/171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587829411053568 |
|---|---|
| author | Arezina Kasti Konstantinos Katsas Maroulla D. Nikolaki Konstantinos Triantafyllou |
| author_facet | Arezina Kasti Konstantinos Katsas Maroulla D. Nikolaki Konstantinos Triantafyllou |
| author_sort | Arezina Kasti |
| collection | DOAJ |
| description | Irritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal tract. Its pathogenesis involves multiple factors, including visceral hypersensitivity and immune activation. NLRP3 inflammasome is part of the nucleotide-binding oligomerization domain-like receptor (NLR) family, a crucial component of the innate immune system. Preclinical studies have demonstrated that inhibiting NLRP3 reduces visceral sensitivity and IBS symptoms, like abdominal pain, and diarrhea, suggesting that targeting the NLRP3 might represent a novel therapeutic approach for IBS. This review aims to assess the NLRP3 inhibitors (tranilast, β-hydroxybutyrate, Chang-Kang-fang, paeoniflorin, coptisine, BAY 11-7082, and <i>Bifidobacterium longum)</i>, highlighting the signaling pathways, and their potential role in IBS symptoms management was assessed. Although premature, knowledge of the action of synthetic small molecules, phytochemicals, organic compounds, and probiotics might make NLRP3 a new therapeutic target in the quiver of physicians’ therapeutic choices for IBS symptoms management. |
| format | Article |
| id | doaj-art-0a6f9a5218ef4e1696422072e0970377 |
| institution | Kabale University |
| issn | 2076-2607 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj-art-0a6f9a5218ef4e1696422072e09703772025-01-24T13:42:55ZengMDPI AGMicroorganisms2076-26072025-01-0113117110.3390/microorganisms13010171The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative ReviewArezina Kasti0Konstantinos Katsas1Maroulla D. Nikolaki2Konstantinos Triantafyllou3Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, GreeceDepartment of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, GreeceDepartment of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, GreeceHepatogastroenterology Unit, 2nd Department of Internal Propaedeutic Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, 12462 Athens, GreeceIrritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal tract. Its pathogenesis involves multiple factors, including visceral hypersensitivity and immune activation. NLRP3 inflammasome is part of the nucleotide-binding oligomerization domain-like receptor (NLR) family, a crucial component of the innate immune system. Preclinical studies have demonstrated that inhibiting NLRP3 reduces visceral sensitivity and IBS symptoms, like abdominal pain, and diarrhea, suggesting that targeting the NLRP3 might represent a novel therapeutic approach for IBS. This review aims to assess the NLRP3 inhibitors (tranilast, β-hydroxybutyrate, Chang-Kang-fang, paeoniflorin, coptisine, BAY 11-7082, and <i>Bifidobacterium longum)</i>, highlighting the signaling pathways, and their potential role in IBS symptoms management was assessed. Although premature, knowledge of the action of synthetic small molecules, phytochemicals, organic compounds, and probiotics might make NLRP3 a new therapeutic target in the quiver of physicians’ therapeutic choices for IBS symptoms management.https://www.mdpi.com/2076-2607/13/1/171irritable bowel syndromeNLRP3 inflammasomevisceral hypersensitivityproinflammatory cytokines |
| spellingShingle | Arezina Kasti Konstantinos Katsas Maroulla D. Nikolaki Konstantinos Triantafyllou The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review Microorganisms irritable bowel syndrome NLRP3 inflammasome visceral hypersensitivity proinflammatory cytokines |
| title | The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review |
| title_full | The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review |
| title_fullStr | The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review |
| title_full_unstemmed | The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review |
| title_short | The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review |
| title_sort | role and the regulation of nlrp3 inflammasome in irritable bowel syndrome a narrative review |
| topic | irritable bowel syndrome NLRP3 inflammasome visceral hypersensitivity proinflammatory cytokines |
| url | https://www.mdpi.com/2076-2607/13/1/171 |
| work_keys_str_mv | AT arezinakasti theroleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT konstantinoskatsas theroleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT maroulladnikolaki theroleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT konstantinostriantafyllou theroleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT arezinakasti roleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT konstantinoskatsas roleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT maroulladnikolaki roleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview AT konstantinostriantafyllou roleandtheregulationofnlrp3inflammasomeinirritablebowelsyndromeanarrativereview |